Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)
Brief Summary: Drug-eluting stents (DES), markedly reducing the neointimal hyperplasia after stent implantation compared with bare-metal stents (BMS), have improved angiographic and clinical outcomes in the complex lesions and patients with high risks. However, currently, the fatal events related with stent thrombosis still occur and are the major limitation of the use of DES. Especially, late or very late thrombosis after DES implantation is an uncommon but life-threatening fatal complication presented with sudden death or myocardial infarction (MI) causing heart failure. The most powerful predictor for stent thrombosis is the discontinuation of clopidogrel. In consideration of current data regarding stent thrombosis and clinical situation of discontinuation of antiplatelet, zotarolimus-eluting stent (ZES) \[Endeavor®, Medtronic Vascular, Santa Rosa, CA\] might be anticipated to be safer than other DES during the long-term follow-up owing to healthy endothelialization. Endeavor® stent was consists of zotarolimus, thin-strut, cobalt-chromium alloy stent platform (DriverTM stent; Medtronic Vascular, Santa Rosa, CA), and phosphorylcholine coating. The ENDEAVOR II study demonstrated clinically and statistically significant improvement in all of study endpoints, including a 47 percent reduction in the primary endpoint of target vessel failure (TVF). In addition, the ENDEAVOR II trial showed a 0.5 percent rate of stent thrombosis at 30 days - with no late thrombosis beyond 30 days and no late stent malapposition. Because reendothelialization after ZES implantation may occur within 3 months, 3-month dual antiplatelet therapy is recommended in many clinical trials and real world practice. Shorter maintenance of dual antiplatelet therapy might minimize the risk for stent thrombosis in cases of discontinuation of antiplatelet and prevent waste medications and bleeding complications related with dual antiplatelet therapy. However, there have been no non-inferior or superior data of ZES considering all these circumstances. Therefore, the investigators hypothesize that ZES with 3-month dual antiplatelet therapy may be safe and beneficial in patients with coronary artery disease during follow-up than other DES, in spite of higher late lumen loss. To test this hypothesis, the investigators will perform a multi-center, randomized, prospective trial aimed at demonstrating the efficacy of the ZES versus other DES in patients with coronary artery disease in real world practice.


Options:
A: Arm Label: aspirin low responders monotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: aspirin low responders dual antiplatelet therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin low responders dual antiplatelet therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 2
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
D: Arm Label: Endeavor arm; Type: EXPERIMENTAL; Interventions: Device: Zotarolimus-eluting stent | Arm Label: Endeavor resolute arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Zotarolimus-eluting stent for ACS and DM | Arm Label: Xience arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent for long lesion | Arm Label: Cypher arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent for short lesion | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent; Assigned to Arm(s): Endeavor arm | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent for ACS and DM; Assigned to Arm(s): Endeavor resolute arm | Intervention Type: DEVICE; Name: Everolimus-eluting stent for long lesion; Assigned to Arm(s): Xience arm | Intervention Type: DEVICE; Name: Sirolimus-eluting stent for short lesion; Assigned to Arm(s): Cypher arm

Answer: D